Pancreatic ductal adenocarcinoma is an aggressive and lethal cancer, with a five-year survival rate of only 13%.
Our research focuses on understanding the mechanisms driving pancreatic cancer progression. We aim to identify key molecular regulators that can be targeted to inhibit primary tumor growth and to elucidate the processes involved in metastatic seeding and formation.
In parallel, we conduct CRISPR/Cas9 screens to identify genes in immune cells that mediate responses to immunosuppressive signals. Targeting these genes holds the potential to enhance the immune system’s ability to combat cancer. We have discovered gene combinations in dendritic cells that improve T-cell priming and are now extending this approach to engineer additional immune cell types for more effective cancer immunotherapy.

Lab manager

Postdoc. student

PhD. student

PhD. student

PhD. student

Undergraduate student

Undergraduate student

Undergraduate student